Nasdaq GlobeNewswire

Interim Data on MobiusHD Presented at the European Society of Cardiology Shows Promise in the Treatment of Resistant Hypertension

Del

MOUNTAIN VIEW, Calif., Aug. 28, 2017 (GLOBE NEWSWIRE) -- Vascular Dynamics, Inc., (VDI) a privately held medical device company developing novel solutions for the treatment of hypertension, today announced interim results of the company's first-in-human trial of its MobiusHD implant presented in a podium presentation at the European Society of Cardiology (ESC) in Barcelona. The data showed an average reduction of ambulatory systolic blood pressure of 20 mmHg from baseline in the first 40 patients (of an anticipated 50) to reach the 6-month endpoint in studies conducted in the US and EU.

These interim results of the CALM-FIM (Controlling and Lowering Blood Pressure with MobiusHD First in Man) trial, provided results from the first cohort of 40 patients evaluated in the United States and Europe. The data demonstrated that at the six-month evaluation point, 88 percent of the 40-patient cohort had a greater than 10 mmHg drop in office systolic blood pressure or 5 mmHg or more in 24-hour ambulatory systolic blood pressure. Many of these patients also experienced a reduction in their use of antihypertensive medication. 

"These interim data show significant promise in treating patients with resistant hypertension, that is, those who remain uncontrolled even after as many as three or more antihypertensive drugs," said Wilko Spiering, MD, internist-vascular medicine specialist, University Medical Center Utrecht, the Netherlands and President of the Dutch Hypertension Society who presented the CALM-FIM data as one of the trial investigators. "Our positive experience with the MobiusHD device demonstrates the need for continued investigation in a sham-controlled setting, which is currently running in the Netherlands and is starting up in the United States, United Kingdom, and Germany shortly."

The interim results presented at the ESC conference will be followed by a study to be published in The Lancet on September 1, 2017, which outlines the final results of the CALM-FIM_EU study.

The MobiusHD System, a minimally-invasive system, capitalizes on the ability of the body's baroreceptor mechanism to regulate blood pressure. Baroreceptors are receptors located in the carotid artery that sense blood pressure and relay that information to the brain. The MobiusHD implant is designed to amplify the signals received by the surrounding arterial baroreceptors, and thereby increase the body's natural response to lower blood pressure through vasodilation.

About Resistant Hypertension
Hypertension, or elevated blood pressure, is a common medical condition that currently affects one billion people worldwide.1 If left untreated, hypertension can cause life-threatening problems, including heart attack, aneurysm, stroke or kidney failure. Patients with hypertension can often reduce their risk factors by making lifestyle changes such as losing weight, quitting smoking, and increased exercise. In cases with advanced hypertension, medical therapies may be prescribed.
Patients experiencing resistant hypertension are uncontrolled with at least 3 antihypertensive drugs and are at four times greater risk of cardiovascular events compared with hypertensive patients achieving blood pressure targets.2 The American Heart Association (AHA) estimates that high blood pressure costs the U.S. $46 billion each year, including the cost of healthcare services, medications to treat high blood pressure, and lost productivity.

About Vascular Dynamics, Inc.
Vascular Dynamics develops catheter-delivered technologies to bring a better quality of life to patients who are resistant to conventional treatments for hypertension. The device is covered by seven issued and pending U.S. and international patents. The MobiusHD system has received a CE Mark for the treatment of hypertension in the European Union. However, the MobiusHD system is not commercially available in the United States.  More information is available at www.vasculardynamics.com.

CAUTION: In the United States, the MobiusHD Device is limited by law to investigational use only.
1 Kearney PM, et al. Global burden of hypertension: Analysis of worldwide data. Lancet. 2005;365(9455):217-23
2 Pierdomenico SD, Lapenna D, Bucci A, et al. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am J Hypertens. 2005;18: 1422-8.

Contact:
Jules Abraham
+1-917-885-7378
jabraham@vasculardynamics.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Vascular Dynamics, Inc. via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

DSM Sinochem Pharmaceuticals launches Atorvastatin film-coated tablets, expanding its finished dosage statins portfolio18.6.2018 11:23Pressemelding

Rijswijk, 18 June 2018, June 18, 2018 (GLOBE NEWSWIRE) -- Building upon its first generic finished dosage statin launch (Rosuvastatin) in January of this year, DSM Sinochem Pharmaceuticals (DSP) has this month released its fully backward-integrated, generic Atorvastatin drug product within the EU. Additional markets are scheduled to follow later in the year.Atorvastatin is used primarily in the prevention of cardiovascular disease and hyperlipidemia, commonly known as high cholesterol, the number one cause of death worldwide. Currently, statins are the most prescribed drug family globally in the fight against these potentially life-threatening conditions. Expanding statins portfolio With the launch now of Atorvastatin finished dosage formulation, coming on the heels of the successful launch of Rosuvastatin in January of 2018, DSP is actively expanding its statins drug product portfolio, realizing its aspiration of becoming a full-service generics pharmaceutical company. What sets DSP a

Juniper Networks Becomes Global Sponsor of World Robot Olympiad18.6.2018 11:00Pressemelding

Global competition that enables tens of thousands of young people to develop invaluable automation and programming skills now includes Engineering Simplicity award SUNNYVALE, Calif., June 18, 2018 (GLOBE NEWSWIRE) -- Juniper Networks (NYSE:JNPR), an industry leader in automated, scalable and secure networks, today announced that it has become the global technology partner of the World Robot Olympiad(TM) Association (WRO®), a non-profit organization that focuses on the hands-on development of robotics within STEM (Science, Technology, Engineering, Math) education on a worldwide scale. In a multi-year agreement, Juniper will work closely with WRO to promote, stage and further develop this global competition that attracts tens of thousands of young people. As part of its involvement in the competition, Juniper will be sponsoring a new trophy at this year's finals, WRO 2018, known as the Juniper Networks' Engineering Simplicity Honors Award. Juniper will judge teams in the Regular category

Skybox Security Continues Winning Streak with Multiple Awards and Honors18.6.2018 09:00Pressemelding

SAN JOSE, Calif., June 18, 2018 (GLOBE NEWSWIRE) -- Skybox (TM) Security, a global leader in cybersecurity management, announced today it won Best Risk Management/Regulatory Compliance Solution at the 2018 SC Awards Europe in addition to the previous win in a similar category at the 2018 SC Awards US held in April. Skybox was also recognized as the "Highly Commended" finalist for Best Vulnerability Management Solution, Skybox(TM) Vulnerability Control, at the U.K. awards show in London on June 5, 2018. These honors add to the multiple awards given to the Skybox(TM) Security Suite, including several five-star reviews by SC Magazine in its Risk and Policy Management and Vulnerability and Threat Management group review categories. "We're delighted once again to be recognized for the hard work our dedicated engineers have put into making our platform a powerful, best-in-class technology. Our continuous innovations of the Suite help organizations keep up with the fast-changing nature of vul

IRIDEOS Acquires Enter18.6.2018 08:35Pressemelding

IRIDEOS Enhances Recent Strategic Acquisitions With Purchase of Leading Italian-Based Network and Cloud Services Provider MILAN, Italy, June 18, 2018 (GLOBE NEWSWIRE) -- IRIDEOS, the new Italian ICT provider for Businesses and Public Administration, announces today the acquisition of Enter, a leader in network and cloud services based in Italy. This purchase is the most recent of IRIDEOS acquisitions as the company works to consolidate the cloud and data center market throughout Italy. "With this new acquisition, our growth path continues, focused on strengthening our assets and skills in the Italian ICT space," says Mauro Maia, CEO of IRIDEOS. "A wider portfolio of services is now available for our customers, with new cloud solutions and international connectivity." As a leading ISP focused on providing global network connectivity, Enter's IP backbone spans 35+ Points of Presence (PoPs) worldwide, providing a wide range of network services, including Ethernet, VPN and cloud interconne

GlobeNewswire Test Release16.6.2018 07:00Pressemelding

LOS ANGELES, June 15, 2018 (GLOBE NEWSWIRE) -- This is a test from GlobeNewswire. Readers are advised to disregard. TESTING -- TESTING -- TESTING -- TESTING -- TESTING -- TESTING -- TESTING -- TESTING – -END- CONTACT: Karen Yu Director, GlobeNewswire Product Management Direct: +1 310 258 6917 Mobile: +1 626 389 7427 or Magali Rolandez Senior Manager, Media Relations/Content Distribution Europe Direct: +44 (0) 203 753 2215 Mobile: +44 (0) 7785 619 539

INVNT/IP: US Responds to Nation-sponsored Crown-jewel Intellectual Property Theft15.6.2018 23:34Pressemelding

US Announcement of Large-Scale Tariffs in Response to Chinese Crown-Jewel Intellectual Property Theft Lauded by IP Protection Consortium INVNT/IP SEATTLE, June 15, 2018 (GLOBE NEWSWIRE) -- The Trump administration today announced 25% tariffs on $50 billion in Chinese goods, representing the first time the United States government has marked sectors in US-China trade for retaliation as a response to theft of crown-jewel intellectual property. In a public statement, President Trump announced that the measures were targeted toward goods that "contain industrially significant technologies." US Trade Representative Robert Lighthizer applauded the move on Fox News, noting, "It's thorough. It's moderate. It's appropriate." In a further explanation of the move, he added, "What I want to do is make sure that we protect our technology here at home, that we stop cybertheft and forced technology transfer, and ultimately, remember: 'China 2025' is a $300 billion subsidy program. The United States h

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom